









Markets
/
Stocks
/
nasdaq-phat
/

Phathom Pharmaceuticals Inc

PHAT

13.960USD

+0.230+1.68%

Market hours （ET）Quotes delayed by 15 min

991.76MMarket Cap

LossP/E TTM



Phathom Pharmaceuticals Inc

13.960

+0.230+1.68%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Phathom Pharmaceuticals Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Phathom Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

65 / 159

Overall Ranking

168 / 4617

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

21.750

Target Price

+60.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Phathom Pharmaceuticals Inc Highlights

StrengthsRisks

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Growing

The company is in a growing phase, with the latest annual income totaling USD 55.25M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 55.25M.

Undervalued

The company’s latest PE is -3.66, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 58.80M shares, decreasing 29.04% quarter-over-quarter.

Held by Louis Moore Bacon

Star Investor Louis Moore Bacon holds 600.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.09.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 6.24, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 49.50M, representing a year-over-year increase of 202.74%, while its net profit experienced a year-over-year increase of 64.98%.

Score

Industry at a Glance

Previous score

6.24

Change



Financials

5.74

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.14

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.26

Key Metrics

Free cash flow

No Data

Phathom Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 6.25, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -3.66, which is -87.92% below the recent high of -0.44 and -2.99% above the recent low of -3.77.

Score

Industry at a Glance

Previous score

6.25

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.44, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Phathom Pharmaceuticals Inc is 20.00, with a high of 29.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

21.750

Target Price

+58.41%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Phathom Pharmaceuticals Inc

PHAT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 8.86, which is higher than the Pharmaceuticals industry's average of 7.00. Sideways: Currently, the stock price is trading between the resistance level at 16.43 and the support level at 10.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.81

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.038

Neutral

RSI(14)

60.240

Neutral

STOCH(KDJ)(9,3,3)

25.171

Sell

ATR(14)

1.044

Low Volatility

CCI(14)

20.720

Neutral

Williams %R

61.518

Sell

TRIX(12,20)

0.652

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

13.532

Buy

MA10

13.607

Buy

MA20

13.009

Buy

MA50

12.343

Buy

MA100

10.894

Buy

MA200

8.023

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 82.89%, representing a quarter-over-quarter decrease of 6.44%. The largest institutional shareholder is The Vanguard, holding a total of 2.79M shares, representing 3.92% of shares outstanding, with 3.29% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

12.19M

-2.21%

Medicxi Ventures (UK) LLP

7.46M

Millennium Management LLC

4.16M

+84.87%

Abingworth Management Limited

3.50M

Invesco Advisers, Inc.

3.24M

-3.20%

BlackRock Institutional Trust Company, N.A.

3.00M

+2.97%

The Vanguard Group, Inc.

Star Investors

2.79M

+0.65%

Ensign Peak Advisors, Inc.

2.52M

+0.23%

683 Capital Management LLC

2.10M

+45.67%

New Enterprise Associates (NEA)

1.96M

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 4.72, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.